-transparent.png){kind=logo}
A patient with IgG3 lambda plasma cell myeloma characterized by anemia, hypercalcemia, hypoalbuminemia, renal insufficiency, osteolytic bone lesions, and serum and urinary light chains inadvertently received a dose of intravenous melphalan considerably greater than standard. A complete remission ensued characterized by normal protein and bone marrow studies. Healing of bone lesions occurred. This and two somewhat similar happenstances producing rare complete remissions in myeloma may have significant chemotherapeutic ramifications.
Related Publications
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
November 1983,
Lancet (London, England),
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
January 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
March 1999,
Bulletin du cancer,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
May 1987,
British journal of haematology,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
May 2023,
Cancers,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
June 1969,
JAMA,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
January 2007,
Transfusion,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
December 1988,
Blood,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
July 2006,
Leukemia & lymphoma,
F Richards, and
M Coleman, and
M R Cooper, and
W P Ballard
April 1983,
European journal of cancer & clinical oncology,
